Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 6;23(7):4044.
doi: 10.3390/ijms23074044.

Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers

Taku Fujimura  1
Affiliations
Review

Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers

Taku Fujimura. Int J Mol Sci. .

Abstract

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1) antibodies (Abs) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) Abs, have been widely administered for not only advanced melanoma, but also various non-melanoma skin cancers. Since profiles of tumor-infiltrating leukocytes (TILs) play important roles in immunotherapy using ICIs, it is important to evaluate cancer stromal cells such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), as well as stromal extracellular matrix protein, to predict the efficacy of ICIs. This review article focuses particularly on TAMs and related factors. Among TILs, TAMs and their related factors could be the optimal biomarkers for immunotherapy such as anti-PD1 Ab therapy. According to the studies presented, TAM-targeting therapies for advanced melanoma and non-melanoma skin cancer will develop in the future.

Keywords: CAF; TAMs; angiogenetic factors; cancer stroma; chemokines.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of TAMs in the melanoma tumor microenvironment.
Figure 2
Figure 2
Schematic representation of TAMs in the EMPD tumor microenvironment.
See this image and copyright information in PMC

References

    1. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2019;381:1535–1546. doi: 10.1056/NEJMoa1910836. - DOI - PubMed
    1. Fujimura T., Kambayashi Y., Ohuchi K., Muto Y., Aiba S. Treatment of Advanced Melanoma: Past, Present and Future. Life. 2020;16:208. doi: 10.3390/life10090208. - DOI - PMC - PubMed
    1. Ishii M., Hirai I., Tanese K., Fusumae T., Nakamura Y., Fukuda K., Uchi H., Kabashima K., Otsuka A., Yokota K., et al. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study) Medicine. 2020;99:e22913. doi: 10.1097/MD.0000000000022913. - DOI - PMC - PubMed
    1. Migden M.R., Khushalani N.I., Chang A.L.S., Lewis K.D., Schmults C.D., Hernandez-Aya L., Meier F., Schadendorf D., Guminski A., Hauschild A., et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305. doi: 10.1016/S1470-2045(19)30728-4. - DOI - PMC - PubMed
    1. Stratigos A.J., Sekulic A., Peris K., Bechter O., Prey S., Kaatz M., Lewis K.D., Basset-Seguin N., Chang A.L.S., Dalle S., et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848–857. doi: 10.1016/S1470-2045(21)00126-1. - DOI - PubMed

Substances